These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 2852947)
61. Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative. Pagani O; Zucchetti M; Sessa C; de Jong J; D'Incalci M; De Fusco M; Kaeser-Fröhlich A; Hanauske A; Cavalli F Cancer Chemother Pharmacol; 1996; 38(6):541-7. PubMed ID: 8823496 [TBL] [Abstract][Full Text] [Related]
62. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703 [TBL] [Abstract][Full Text] [Related]
63. Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer. Ghielmini M; Pagani O; de Jong J; Pampallona S; Conti A; Maestroni G; Sessa C; Cavalli F Br J Cancer; 1999 Jun; 80(7):1058-61. PubMed ID: 10362116 [TBL] [Abstract][Full Text] [Related]
64. [Pharmacokinetic study and side effects of chronic daily administration of oral etoposide]. Taguchi O; Yamakami T; Machishi M; Gabazza EC; Ibata H; Tsutsui K; Suzuki S Gan To Kagaku Ryoho; 1992 Oct; 19(12):2005-9. PubMed ID: 1329670 [TBL] [Abstract][Full Text] [Related]
65. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group. Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577 [TBL] [Abstract][Full Text] [Related]
66. [Pharmacokinetic study of etoposide in aged patient with non Hodgkin lymphoma receiving hemodialysis]. Miyaoka K; Matsubara T; Matsumoto T; Kanda C Gan To Kagaku Ryoho; 1991 Oct; 18(13):2325-8. PubMed ID: 1929451 [TBL] [Abstract][Full Text] [Related]
67. Is there a circadian variation in plasma concentrations of etoposide given by prolonged continuous infusion? Ando Y; Minami H; Sakai S; Shimokata K Cancer Chemother Pharmacol; 1996; 37(6):616-8. PubMed ID: 8612319 [TBL] [Abstract][Full Text] [Related]
68. Dose-escalation study of oral etoposide and carboplatin in patients with advanced lung cancer. Atagi S; Furuse K; Kawahara M; Kodama N; Ogawara M; Kubota K; Matsui K; Kusunoki Y; Masuda N; Takada M; Negoro S; Fukuoka M Jpn J Clin Oncol; 1996 Oct; 26(5):316-21. PubMed ID: 8895671 [TBL] [Abstract][Full Text] [Related]
69. Phase II study of ifosfamide, carboplatin, etoposide and GM-CSF in small cell lung cancer. Thongprasert S J Med Assoc Thai; 2000 May; 83(5):549-53. PubMed ID: 10863902 [TBL] [Abstract][Full Text] [Related]
70. Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. Mross K; Hüttmann A; Herbst K; Hanauske AR; Schilling T; Manegold C; Burk K; Hossfeld DK Cancer Chemother Pharmacol; 1996; 38(3):217-24. PubMed ID: 8646795 [TBL] [Abstract][Full Text] [Related]
71. Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule. Perdaems N; Bachaud JM; Rouzaud P; Murris-Espin M; Hermant C; Mihura J; Lochon I; Houin G; Canal P; Chatelut E Eur J Clin Pharmacol; 1998; 54(9-10):677-83. PubMed ID: 9923567 [TBL] [Abstract][Full Text] [Related]
72. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer. Bunn PA; Kelly K Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-144-S12-148. PubMed ID: 9331140 [TBL] [Abstract][Full Text] [Related]
73. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. You B; Tranchand B; Girard P; Falandry C; Ribba B; Chabaud S; Souquet PJ; Court-Fortune I; Trillet-Lenoir V; Fournel C; Tod M; Freyer G Lung Cancer; 2008 Nov; 62(2):261-72. PubMed ID: 18442869 [TBL] [Abstract][Full Text] [Related]
75. Phase I clinical and pharmacokinetic study of oral etoposide phosphate. Sessa C; Zucchetti M; Cerny T; Pagani O; Cavalli F; De Fusco M; De Jong J; Gentili D; McDaniel C; Prins C J Clin Oncol; 1995 Jan; 13(1):200-9. PubMed ID: 7799021 [TBL] [Abstract][Full Text] [Related]
76. Preliminary study of efficacy of intravenous cisplatin plus oral etoposide in small cell lung cancer. Chewaskulyong B; Thongprasert S J Med Assoc Thai; 1998 Jan; 81(1):37-41. PubMed ID: 9470320 [TBL] [Abstract][Full Text] [Related]
77. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. Schiller JH; Kim K; Hutson P; DeVore R; Glick J; Stewart J; Johnson D J Clin Oncol; 1996 Aug; 14(8):2345-52. PubMed ID: 8708727 [TBL] [Abstract][Full Text] [Related]
78. A randomized study of etoposide and carboplatin with or without paclitaxel in the treatment of small cell lung cancer. Birch R; Weaver CH; Hainsworth JD; Bobo C; Greco FA Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-135-S12-137. PubMed ID: 9331138 [TBL] [Abstract][Full Text] [Related]
79. Pharmacological analysis of etoposide in elderly patients with lung cancer. Ando M; Minami H; Ando Y; Sakai S; Shimono Y; Sugiura S; Saka H; Shimokata K; Hasegawa Y Clin Cancer Res; 1999 Jul; 5(7):1690-5. PubMed ID: 10430070 [TBL] [Abstract][Full Text] [Related]
80. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: a University of Colorado Cancer Center study. Bunn PA; Kelly KL Semin Oncol; 1995 Oct; 22(5 Suppl 12):54-8; discussion 59-60. PubMed ID: 7481862 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]